Net Efficacy Adjusted for Risk (NEAR): A Simple Procedure for Measuring Risk:Benefit Balance
Authors:
- José N. BoadaJBJosé N. Boada
- Mar García-SáizMGMar García-Sáiz
- Eduardo FernándezEduardo Fernández
Open Access
- 31 October 2008
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 3 (10) , e3580
Abstract
Although several mathematical models have been proposed to assess the risk:benefit of drugs in one measure, their use in practice has been rather limited. Our objective was to design a simple, easily applicable model. In this respect, measuring the proportion of patients who respond favorably to treatment without being affected by adverse drug reactions (ADR) could be a suitable endpoint. However, remarkably few published clinical trials report the data required to calculate this proportion. As an approach to the problem, we calculated the expected proportion of this type of patients. Theoretically, responders without ADR may be obtained by multiplying the total number of responders by the total number of subjects that did not suffer ADR, and dividing the product by the total number of subjects studied. When two drugs are studied, the same calculation may be repeated for the second drug. Then, by constructing a 2×2 table with the expected frequencies of responders with and without ADR, and non-responders with and without ADR, the odds ratio and relative risk with their confidence intervals may be easily calculated and graphically represented on a logarithmic scale. Such measures represent “net efficacy adjusted for risk” (NEAR). We assayed the model with results extracted from several published clinical trials or meta-analyses. On comparing our results with those originally reported by the authors, marked differences were found in some cases, with ADR arising as a relevant factor to balance the clinical benefit obtained. The particular features of the adverse reaction that must be weighed against benefit is discussed in the paper. NEAR representing overall risk-benefit may contribute to improving knowledge of drug clinical usefulness. As most published clinical trials tend to overestimate benefits and underestimate toxicity, our measure represents an effort to change this trend.Keywords
This publication has 16 references indexed in Scilit:
- The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trialsCanadian Medical Association Journal, 2008
- Analysis of a binary composite endpoint with missing data in componentsStatistics in Medicine, 2007
- Ibuprofeno frente a indometacina en el tratamiento del conducto arterioso persistente del prematuroAnales de Pediatría, 2005
- Odds Ratio, Relative Risk, Absolute Risk Reduction, and the Number Needed to Treat—Which of These Should We Use?Value in Health, 2002
- Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacinJournal of Antimicrobial Chemotherapy, 2001
- ‘Unqualified Success’ and ‘Unmitigated Failure’ Number-Needed-to-Treat-Related Concepts for Assessing Treatment Efficacy in the Presence of Treatment-Induced Adverse EventsInternational Journal of Epidemiology, 1996
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- COMPARING THE BIVARIATE EFFECTS OF TOXICITY AND EFFICACY OF TREATMENTSStatistics in Medicine, 1995
- Three measures for simultaneously evaluating benefits and risks using categorical data from clinical trialsStatistics in Medicine, 1991
- An Assessment of Clinically Useful Measures of the Consequences of TreatmentNew England Journal of Medicine, 1988